Happle R, van de Kerkhof P C, Traupe H
Department of Dermatology, University of Nijmegen, The Netherlands.
Dermatologica. 1987;175 Suppl 1:107-24. doi: 10.1159/000248867.
Hereditary disorders of keratinization may be a considerable handicap. Oral treatment with retinoids has been shown to be effective in many of these diseases. In the group of ichthyoses, the best results can be obtained in the various types of nonbullous congenital ichthyosis (erythrodermic autosomal recessive lamellar ichthyosis, nonerythrodermic autosomal recessive lamellar ichthyosis, autosomal dominant lamellar ichthyosis). It should be borne in mind, however, that retinoid therapy alone cannot lead to a complete response of these forms of ichthyosis and that this treatment cannot replace an appropriate topical treatment. During continuous treatment with etretinate a reduction of the dosis to 0.5 mg/kg is often necessary. Etretinate treatment of bullous congenital ichthyosiform erythroderma is more difficult, and it is advisable to begin with a low dosis of 0.25-0.5 mg/kg. The epidermolytic form of palmoplantar keratoderma is in our opinion no indication for retinoid treatment which seems to result inevitably in large erosions. Good or excellent results have been seen in other forms of palmoplantar keratoderma including mal de Meleda, Papillon-Lefèvre syndrome, erythrokeratodermia variabilis, verrucous epidermal nevi, Darier disease and pityriasis rubra pilaris. In patients with Darier disease it is wise to begin with a relatively low dosage of 0.5 mg/kg and to adjust the dosage to the further course of the disease. The same is true for the ichthyosis seen in the Netherton syndrome, which may be either a diffuse hyperkeratosis or ichthyosis linearis circumflexa. In view of the fact that any inherited keratinization disorder requires long-term treatment, the risk of bone toxicity should be carefully weighed against the benefit of this therapy. The results so far obtained indicate that the effect of etretin is comparable to that of etretinate in the treatment of inherited keratinization disorders. Intermittent therapy should be tried whenever possible. A combination therapy seems reasonable in pityriasis rubra pilaris of the adult type. We have seen good results by combination with PUVA treatment. Autosomal dominant ichthyosis vulgaris and X-linked recessive ichthyosis are inappropriate to treat with oral retinoid therapy because these diseases are too mild. Papillomatous epidermal nevi should also be excluded because they do not respond to the drug. Hailey-Hailey disease may even be worsened by this treatment. According to our experience, oral retinoid therapy has no effect in monilethrix.
角化遗传性疾病可能是一个相当大的障碍。已证明用维甲酸进行口服治疗对其中许多疾病有效。在鱼鳞病组中,在各种非大疱性先天性鱼鳞病(红皮病型常染色体隐性板层状鱼鳞病、非红皮病型常染色体隐性板层状鱼鳞病、常染色体显性板层状鱼鳞病)中可获得最佳效果。然而,应记住,仅用维甲酸治疗不能使这些鱼鳞病完全缓解,且这种治疗不能替代适当的局部治疗。在用依曲替酯持续治疗期间,常需将剂量减至0.5mg/kg。用依曲替酯治疗大疱性先天性鱼鳞病样红皮病更困难,宜从0.25 - 0.5mg/kg的低剂量开始。在我们看来,掌跖角化病的表皮松解型不是维甲酸治疗的适应证,因为这似乎不可避免地会导致大面积糜烂。在其他类型的掌跖角化病中,包括梅勒达病、帕皮永 - 勒费弗尔综合征、可变性红斑角皮症、疣状表皮痣、 Darier病和毛发红糠疹,已观察到良好或极佳的效果。对于患有Darier病的患者,明智的做法是从相对较低的剂量0.5mg/kg开始,并根据疾病的进一步发展调整剂量。 Netherton综合征中出现的鱼鳞病也是如此,它可能是弥漫性角化过度或回旋状线状鱼鳞病。鉴于任何遗传性角化病都需要长期治疗,应仔细权衡骨毒性风险与这种治疗的益处。迄今获得的结果表明阿维A在治疗遗传性角化病方面的效果与依曲替酯相当。只要有可能,应尝试间歇治疗。对于成人型毛发红糠疹,联合治疗似乎是合理的。我们通过与PUVA治疗联合已观察到良好效果。常染色体显性寻常型鱼鳞病和X连锁隐性鱼鳞病不适用于口服维甲酸治疗,因为这些疾病太轻微。疣状表皮痣也应排除在外,因为它们对该药物无反应。 Hailey - Hailey病甚至可能因这种治疗而恶化。根据我们的经验,口服维甲酸治疗对念珠状发无效。